Radiofrequency ablation using a 10‐mm target margin for small hepatocellular carcinoma in patients with liver cirrhosis: A prospective randomized trial. Issue 8 (23rd March 2017)

• Record Type: Journal Article
• Authors: Liao, Mingheng; Zhong, Xiaofei; Zhang, Jingyi; Liu, Yangyang; Zhu, Zexin; Wu, Hong; Zeng, Yong; Huang, Jiwei
• Is Part Of: Journal of surgical oncology. Volume 115:Issue 8(2017)
• Page Start: 971
• Page End: 979
• Publication Date: 2017-03-23
• Subjects: hepatocellular carcinoma -- liver cirrhosis -- margin -- radiofrequency ablation -- recurrence; Cancer -- Surgery -- Periodicals; Neoplasms -- Periodicals; 616
• DOI: 10.1002/jso.24607
• Languages: English
• ISSNs: 0022-4790

Abstract

Abstract : Background And Objectives: To compare 3‐year clinical outcomes of radiofrequency ablation (RFA) targeting 5‐ or 10‐mm margins for small hepatocellular carcinomas (HCCs) in cirrhotic patients. Methods: In total, 96 cirrhotic patients with a small solitary HCC (diameter ≤3 cm) were included in this prospective trial (ChiCTRTRC‐10000954). Patients were stratified by Child‐Pugh class and randomly allocated into groups targeting either wide margins (≥10 mm, WM) or narrow margins (≥5 mm but <10 mm, NM). RFA was performed under real‐time monitoring, and ablative margins were evaluated by pre‐ and post‐operative three‐dimensional registration on CT. Results: The mean follow‐up time was 38.3 ± 4.8 months, 83.3% (40/48) of patients succeeded in obtaining a 10‐mm margin in WM group. Based on intention‐to‐treat analysis, the 3‐year incidences of local tumor progression (LTP) (14.9% vs 30.2%), intrahepatic recurrence (IHR) (15.0% vs 32.7%), and recurrence‐free survival (RFS) (31.7 ± 12.1 vs 24.0 ± 11.7 months) for WM group were significantly improved compared to NM group. Several prognostic factors were identified from univariate and multivariate analyses. Additionally, cirrhosis‐stratified subgroup analyses demonstrated significant survival benefits of WM in patients with Child‐Pugh class B cirrhosis. Conclusions: RFA treatment targeting 10‐mm margin may reduce the risk of tumor recurrence in cirrhotic patients with a single small HCC.